All acknoledgements matter, including a thank-you letter from an organization like ⁦ASCO⁩ !

I was lucky, shortly after my arrival Dana-Farber News , to be involved in that project led by Alejandro Gutierrez Boston Children's and Harvard Medical School , exploring the role of METTL1 gene in sarcomagenesis. From bench to the bedside, hopefully!

secure-web.cisco.com/1BICXlD8J2vNrW…

That needs so much to be emphasized!

Nice work, Philippos Apolinario Costa, MD !

Maybe anti-PD-1 Ab and anti-PD-L1 Ab have equal efficacy, after all, hitting the same pathway but different targets. Not expecting any direct comparison between the two. Clearly, ICI + chemo improves survival in PD-L1 + metastatic GEA.

Waiting for the data of the Alliance randomized trial (temozolomide/olaparib vs. standard chemotherapy), which did not meet its endpoint. In the meantime, useful data. pubmed.ncbi.nlm.nih.gov/40117531/?utm_…

Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial dlvr.it/TK5GkQ #sarcoma #leiomyosarcoma

A great collaboration for which I am thankful to my coauthors Research Institute of the MUHC (The Institute) . That trial was investigator-initiated and taught us many lessons in the processes of design, execution and oversight of clinical and translational research.

🧪Promising results from a new clinical trial! Adding a PD-L1 inhibitor to chemo before surgery may improve outcomes for advanced gastroesophageal cancer. Led by Dr. Alcindor & Dr. Ferri 🔗 Read more: rimuhc.ca/en/-/immunothe…

Enormously honoured to have been included in this study. Safety & feasibility of avelumab+DCF clearly shown and the urgent need to identify novel biomarkers to personalise treatment highlighted! Amazing project & leadership Lorenzo Ferri MD PhD Thierry Alcindor, MD, MSc cell.com/cell-reports-m…

I disagree with the statement that nivo demonstrated OS survival improvement in Checkmate577, when the CI overlaps 1! I agree nivo is a clinically useful agent after CRT, especially for esoph SCC. While an ⬆️ OS is plausible, the data presented do not prove it.

Great oral presentation by ⁦Kohei shitara⁩ . New SOC for HER2 metastatic GEA. Was persistence of HER2 after 1st-line treatment required? nejm.org/doi/full/10.10…

The spectacular view of downtown Chicago from the suite where ⁦JAMA Oncology⁩ hosted a nice reception for its editorial staff and its reviewers.

An interesting trial of anlotinib + epirubicin vs epiribicin in metastatic STS. Promising combination but low ORR (3%) with single agent raises questions about which subtypes were studied. #ASCO24

What a tour de force to complete that study! I remember the patience with which C. Booth would update us at the yearly ⁦CCTG⁩ meetings. Congratulations to the investigators for such an innovative and practice-changing trial. nejm.org/doi/full/10.10…

A positive periop trial with durva + FLOT in GEA. New standard. Happy to see that this phase 3 trial also confirmed the findings of our own IIT phase 2 study with avelumab + mDCF!

That was a great discussion led by Jeroen Dekervel . Thanks to ESMO - Eur. Oncology for the invitation!

A rewarding hike in the beautiful Berkshire mountains!

A rewarding hike in the beautiful Berkshires!